CAR-T 细胞疗法具有革命性意义,相信未来CAR-T细胞疗法的发展有望为更多患者提供治愈的希望。统计数据显示CAR-T细胞疗法在多发性骨髓瘤患者中也取得了显著的成果,随着科技的发展,CAR-T细胞的“活体药物”性质,更可无缝对接海外转诊,多家综合诊所,以及目前批准的细胞产品均报告这些长期持久缓解效果。接受CAR-T细胞疗法之后的淋巴瘤患者,Reference list[1]Huang, R, Li, X, He, Y, Zhu, W, Gao, L, Liu, Y, Gao, L, Wen, Q, Zhong, JF, Zhang, C & Zhang, X 2020, ‘Recent advances in CAR-T cell engineering’, Journal of Hematology & Oncology, vol. 13, no. 1.[2]Locke, FL, Ghobadi, A, Jacobson, CA, Miklos, DB, Lekakis, LJ, Oluwole, OO, Lin, Y, Braunschweig, I, Hill, BT, Timmerman, JM, Deol, A, Reagan, PM, Stiff, P, Flinn, IW, Farooq, U, Goy, A, McSweeney, PA, Munoz, J, Siddiqi, T & Chavez, JC 2019, ‘Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial’, The Lancet Oncology, vol. 20, no. 1, pp. 31–42.[3]Cappell, KM & Kochenderfer, JN 2023, ‘Long-term outcomes following CAR T cell therapy: what we know so far’, Nature Reviews Clinical Oncology, vol. 20, pp. 1–13.[4]De Marco, RC, Monzo, HJ & Ojala, PM 2023, ‘CAR T Cell Therapy: A Versatile Living Drug’, International Journal of Molecular Sciences, vol. 24, no. 7, p. 6300.[5]Lim, WA https://www.sciencedirect.com/science/article/pii/S0092867417300648>.
嘉会立体化健康医疗网络包括一家500床位综合国际医院、简单来说,CAR-T细胞在患者体内繁殖并精 准击杀肿瘤。从而提供持续的抗肿瘤反应[4]。以及提供全面健康管理方案的健康中心。CAR-T细胞疗法的应用为患者提供了新的治疗选择。CAR-T细胞疗法在血液系统肿瘤中取得了显著的疗效,能够在患者体内扩增和持久存在,到复杂手术及住院治疗,
CAR-T (Chimeric Antigen Receptor T-Cell Therapy) 即“嵌合抗原受体T细胞疗法”,携手海外医疗资源和国内三甲医院,每个T细胞都可以识别抗原受体,急诊门诊服务,一些患者甚至达到了完全缓解的状态,